Macquarie Group Ltd. increased its holdings in United Therapeutics Corporation (NASDAQ:UTHR) by 14.4% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 12,700 shares of the biotechnology company’s stock after buying an additional 1,600 shares during the period. Macquarie Group Ltd.’s holdings in United Therapeutics were worth $1,488,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. State of Wisconsin Investment Board bought a new position in United Therapeutics in the 2nd quarter valued at $5,256,000. Comerica Bank boosted its holdings in United Therapeutics by 1.3% in the 2nd quarter. Comerica Bank now owns 35,249 shares of the biotechnology company’s stock valued at $4,635,000 after purchasing an additional 458 shares during the period. River & Mercantile Asset Management LLP bought a new position in United Therapeutics in the 2nd quarter valued at $908,000. Sumitomo Mitsui Trust Holdings Inc. boosted its holdings in United Therapeutics by 2.3% in the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 123,016 shares of the biotechnology company’s stock valued at $15,959,000 after purchasing an additional 2,762 shares during the period. Finally, Captrust Financial Advisors bought a new position in United Therapeutics in the 2nd quarter valued at $925,000. 99.94% of the stock is owned by institutional investors.
In other United Therapeutics news, Director Christopher Causey sold 580 shares of the business’s stock in a transaction dated Thursday, December 7th. The shares were sold at an average price of $134.72, for a total value of $78,137.60. Following the transaction, the director now owns 1,555 shares in the company, valued at $209,489.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Martine A. Rothblatt sold 1,274 shares of the business’s stock in a transaction dated Thursday, September 21st. The shares were sold at an average price of $116.07, for a total transaction of $147,873.18. Following the completion of the transaction, the chief executive officer now owns 2,343 shares in the company, valued at approximately $271,952.01. The disclosure for this sale can be found here. In the last quarter, insiders sold 22,668 shares of company stock worth $2,755,406. 7.80% of the stock is owned by corporate insiders.
Several brokerages have commented on UTHR. BidaskClub raised shares of United Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday. ValuEngine raised shares of United Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, November 30th. Cowen reaffirmed a “hold” rating and set a $129.00 price objective on shares of United Therapeutics in a report on Friday, October 27th. HC Wainwright reaffirmed a “hold” rating and set a $95.00 price objective on shares of United Therapeutics in a report on Thursday, October 26th. Finally, Zacks Investment Research raised shares of United Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, October 9th. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and three have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $136.10.
United Therapeutics Corporation (NASDAQ:UTHR) opened at $137.07 on Friday. The company has a market cap of $5,800.65, a price-to-earnings ratio of 11.84 and a beta of 1.42. United Therapeutics Corporation has a 52-week low of $112.01 and a 52-week high of $169.89.
United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, October 25th. The biotechnology company reported $6.27 EPS for the quarter, topping analysts’ consensus estimates of $4.01 by $2.26. The company had revenue of $445.50 million for the quarter, compared to analysts’ expectations of $426.43 million. United Therapeutics had a net margin of 30.50% and a return on equity of 26.24%. The firm’s revenue was up 9.1% compared to the same quarter last year. During the same quarter last year, the company earned $4.23 EPS. analysts expect that United Therapeutics Corporation will post 12.45 earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: This news story was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright and trademark laws. The correct version of this news story can be read at https://www.dispatchtribunal.com/2017/12/08/macquarie-group-ltd-has-1-49-million-position-in-united-therapeutics-corporation-uthr.html.
United Therapeutics Company Profile
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).
Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR).
Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.